Physician profile
Robert E Barden
NPI 1043322605
$2,793.11
in general payments reported to CMS, 2019-2025
18 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.89 · 2020: $251 · 2021: $300 · 2022: $1,520 · 2023: $456 · 2024: $120 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $693.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $692.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,142.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $256.91 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $195.85 | 2019-2023 | Xarelto |
| Amgen INC. | $185.28 | 2020-2025 | Repatha, Repatha |
| Abiomed | $158.96 | 2023-2024 | Impella |
| Pfizer INC. | $157.01 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.90 | 2020-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $130.71 | 2020-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.07 | 2019-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $90.83 | 2020-2025 | |
| Kowa Pharmaceuticals America, INC. | $45.68 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $29.37 | 2022 | |
| Esperion Therapeutics, INC. | $28.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $27.34 | 2021-2022 | |
| Stryker Corporation | $22.63 | 2025 | Flowtriever |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $22.11 | 2025 | Assure Wcd |
| Chiesi USA, INC. | $21.76 | 2023 | Kengreal |
| Abbott Laboratories | $16.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.